Treatment of Acute Graft-versus-Host Disease in Liver Transplant Recipients
Acute graft-versus-host disease (aGvHD) is a rare complication of liver transplantation associated with high morbidity and mortality. Death typically occurs due to complications related to severe infection, shock, and multiorgan failure. The clinical presentation involves dysfunction of multiple org...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Case Reports in Transplantation |
| Online Access: | http://dx.doi.org/10.1155/2021/8981429 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565676770852864 |
|---|---|
| author | Edward Kim Alina Adeel Adel Bozorgzadeh Shinya Amano Curtis T. Barry Jennifer S. Daly Deepika Devuni Zendee Elaba Laura Houk Paulo N. Martins Babak Movahedi Muthalagu Ramanathan Nicole M. Theodoropoulos |
| author_facet | Edward Kim Alina Adeel Adel Bozorgzadeh Shinya Amano Curtis T. Barry Jennifer S. Daly Deepika Devuni Zendee Elaba Laura Houk Paulo N. Martins Babak Movahedi Muthalagu Ramanathan Nicole M. Theodoropoulos |
| author_sort | Edward Kim |
| collection | DOAJ |
| description | Acute graft-versus-host disease (aGvHD) is a rare complication of liver transplantation associated with high morbidity and mortality. Death typically occurs due to complications related to severe infection, shock, and multiorgan failure. The clinical presentation involves dysfunction of multiple organ systems with overlapping symptoms that often results in a diagnostic delay. As there are a limited number of cases reported in the literature, there are no clear guidelines for treatment. Many different therapeutic measures have been utilized that target various immune system pathways, but steroids remain the first line of therapy. We report on two patients who developed aGvHD after liver transplantation who were treated with ruxolitinib, a novel Janus kinase 1/2 (JAK) inhibitor that has been shown to improve outcomes in steroid refractory cases of aGvHD after allogenic hematopoietic stem cell transplantation. We reviewed the literature to discuss various therapeutic options currently available for aGvHD after liver transplantation. |
| format | Article |
| id | doaj-art-d09be85576fd47e19f7dc92677e7fbc6 |
| institution | Kabale University |
| issn | 2090-6951 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Transplantation |
| spelling | doaj-art-d09be85576fd47e19f7dc92677e7fbc62025-02-03T01:07:07ZengWileyCase Reports in Transplantation2090-69512021-01-01202110.1155/2021/8981429Treatment of Acute Graft-versus-Host Disease in Liver Transplant RecipientsEdward Kim0Alina Adeel1Adel Bozorgzadeh2Shinya Amano3Curtis T. Barry4Jennifer S. Daly5Deepika Devuni6Zendee Elaba7Laura Houk8Paulo N. Martins9Babak Movahedi10Muthalagu Ramanathan11Nicole M. Theodoropoulos12Department of SurgeryDepartment of MedicineDepartment of SurgeryDepartment of PathologyDepartment of MedicineDepartment of MedicineDepartment of MedicineDepartment of PathologyDepartment of DermatologyDepartment of SurgeryDepartment of SurgeryDepartment of MedicineDepartment of MedicineAcute graft-versus-host disease (aGvHD) is a rare complication of liver transplantation associated with high morbidity and mortality. Death typically occurs due to complications related to severe infection, shock, and multiorgan failure. The clinical presentation involves dysfunction of multiple organ systems with overlapping symptoms that often results in a diagnostic delay. As there are a limited number of cases reported in the literature, there are no clear guidelines for treatment. Many different therapeutic measures have been utilized that target various immune system pathways, but steroids remain the first line of therapy. We report on two patients who developed aGvHD after liver transplantation who were treated with ruxolitinib, a novel Janus kinase 1/2 (JAK) inhibitor that has been shown to improve outcomes in steroid refractory cases of aGvHD after allogenic hematopoietic stem cell transplantation. We reviewed the literature to discuss various therapeutic options currently available for aGvHD after liver transplantation.http://dx.doi.org/10.1155/2021/8981429 |
| spellingShingle | Edward Kim Alina Adeel Adel Bozorgzadeh Shinya Amano Curtis T. Barry Jennifer S. Daly Deepika Devuni Zendee Elaba Laura Houk Paulo N. Martins Babak Movahedi Muthalagu Ramanathan Nicole M. Theodoropoulos Treatment of Acute Graft-versus-Host Disease in Liver Transplant Recipients Case Reports in Transplantation |
| title | Treatment of Acute Graft-versus-Host Disease in Liver Transplant Recipients |
| title_full | Treatment of Acute Graft-versus-Host Disease in Liver Transplant Recipients |
| title_fullStr | Treatment of Acute Graft-versus-Host Disease in Liver Transplant Recipients |
| title_full_unstemmed | Treatment of Acute Graft-versus-Host Disease in Liver Transplant Recipients |
| title_short | Treatment of Acute Graft-versus-Host Disease in Liver Transplant Recipients |
| title_sort | treatment of acute graft versus host disease in liver transplant recipients |
| url | http://dx.doi.org/10.1155/2021/8981429 |
| work_keys_str_mv | AT edwardkim treatmentofacutegraftversushostdiseaseinlivertransplantrecipients AT alinaadeel treatmentofacutegraftversushostdiseaseinlivertransplantrecipients AT adelbozorgzadeh treatmentofacutegraftversushostdiseaseinlivertransplantrecipients AT shinyaamano treatmentofacutegraftversushostdiseaseinlivertransplantrecipients AT curtistbarry treatmentofacutegraftversushostdiseaseinlivertransplantrecipients AT jennifersdaly treatmentofacutegraftversushostdiseaseinlivertransplantrecipients AT deepikadevuni treatmentofacutegraftversushostdiseaseinlivertransplantrecipients AT zendeeelaba treatmentofacutegraftversushostdiseaseinlivertransplantrecipients AT laurahouk treatmentofacutegraftversushostdiseaseinlivertransplantrecipients AT paulonmartins treatmentofacutegraftversushostdiseaseinlivertransplantrecipients AT babakmovahedi treatmentofacutegraftversushostdiseaseinlivertransplantrecipients AT muthalaguramanathan treatmentofacutegraftversushostdiseaseinlivertransplantrecipients AT nicolemtheodoropoulos treatmentofacutegraftversushostdiseaseinlivertransplantrecipients |